The duration of clopidogrel are understandably cautious, given the present uncertainty and catastrophic nature of stent thrombosis. Nevertheless, quantification of the actual risk of ‘premature’ clopidogrel discontinuation is elusive, and both financial and bleeding costs are often ignored. Ongoing clinical trials will provide insight, however, and newer antiplatelet agents and second-generation DESs may attenuate fears of stent thrombosis.

Conflict of interest: none declared.

References
The list of references is available in the online version of this paper.